is Director of the Center for Sarcoma and Bone Oncology at the Dana-Farber/Brigham & Women’s Cancer Center, and Senior Vice President for Experimental Therapeutics at the Dana-Farber Cancer Institute. He serves on the Presidential Advisory Cabinet, as well as the Executive Committee of the Clinical Research Institute, both at the Dana-Farber Cancer Institute. Dr. Demetri is also Associate Director of Clinical Investigation for the global Ludwig Institute for Cancer Research and Associate Professor of Medicine, Harvard Medical School in Boston.

A graduate of Harvard College, Dr. Demetri earned a medical degree from the Stanford University School of Medicine in Palo Alto, CA. He then pursued an internship and residency training in internal medicine at the University of Washington Hospitals in Seattle, where he was appointed chief resident in medicine.

His principal research interests are in the discovery and development of novel, molecular targeted therapeutics for the treatment of solid tumors, including GIST and other forms of sarcomas. He is involved in clinical trial investigations for emerging agents of potential value in cancer therapy.

A member of several important medical societies, including the American Society of Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research, and the American College of Physicians, Dr. Demetri also is Vice Chair of the Intergroup Coalition Against Sarcoma and a member of the Medical Advisory Board of the Sarcoma Foundation of America.

A significant contributor to the GI oncology literature, Dr. Demetri has authored or co-authored over 70 journal articles, 14 book chapters and numerous abstracts, reviews and editorials. He serves as an editor or as an editorial board member as a sarcoma reviewer for several highly respected, peer-reviewed journals including the Journal of Clinical Oncology, The Cancer Journal: The Journal of Principles & Practice of Oncology, Update on Cancer Therapeutics, and is the sarcoma section editor for the website of the American Society of Clinical Oncology.

is an Assistant Professor of Surgery at Harvard Medical School and an Associate Surgeon in the Division of Surgical Oncology at Brigham and Women’s Hospital (BWH) and in the Center for Surgery and Bone Oncology at the Dana-Farber Cancer Institute (DFCI). Dr. Raut graduated from Stanford University in Palo Alto, CA with a B.A. in history and a B.S. in biological sciences. He earned a master of science degree in biochemistry at Oxford University. He then obtained his medical degree from Harvard Medical School. Dr. Raut completed his internship and residency in general surgery at the Massachusetts General Hospital (MGH) in Boston, MA. He then completed a postdoctoral fellowship and clinical fellowship in surgical oncology at the M.D. Anderson Cancer Center in Houston, TX where he also served as the administrative fellow.

Dr. Raut’s research and clinical work have contributed to his international reputation in the surgical management of GIST and soft tissue sarcomas. His research focuses on clinical and laboratory studies to minimize local and locoregional recurrence of sarcomas using adjuvant treatment strategies. In addition, he serves as a mentor to physicians-in-training as Director of the Surgical Oncology Fellowship Program at DFCI, BWH, and MGH.

An invited speaker at local, regional, national, and international forums, Dr. Raut addresses multimodal strategies and surgical advances in the management of GIST and other sarcomas.

He is widely published in leading scientific journals and is a prolific contributor to the surgical oncology literature. He is the Associate Section Editor for Bone and Soft Tissue Sarcoma for Annals of Surgical Oncology and an associate editor for the journal Sarcoma. He serves as an ad-hoc reviewer for Annals of Surgery, Cancer, Journal of Clinical Oncology, Journal of Surgical Oncology, and Journal of the American College of Surgeons, among other journals.

is Director of Soft Tissue Pathology at the Cleveland Clinic. He received both a doctorate and medical degree from Cornell University Medical College, and then pursued a residency in anatomic pathology at Brigham and Women’s Hospital (BWH). He received 2 fellowships, the first in soft tissue pathology at BWH, and next in bone pathology at the Mayo Clinic in Rochester, MN. Dr. Rubin also underwent postdoctoral research training at BWH.

Dr. Rubin has dedicated his career to a better understanding of the diagnosis and classification of soft tissue neoplasms, especially sarcomas, where he is a prominent figure nationally and internationally. He is widely regarded as a thought leader in the field and is a founding member of the International Society of Bone and Soft Tissue Pathology. His laboratory is focused on understanding the pathogenesis of sarcomas with the major aim of developing targeted therapies.

He was a member of the working group that authored the WHO Classification of Tumours of Bone and Soft Tissue in 2002, and is well known for his work on gastrointestinal stromal tumor (GIST). Dr. Rubin has developed a genetically engineered mouse GIST model and has been exploring signal transduction and targeted molecular therapies in this model. Furthermore, he has been using this model to understand primary mechanisms of resistance to imatinib mesylate, tackling the important question of how GISTs survive “successful” imatinib therapy.

Dr. Rubin has published over 100 peer reviewed journal articles and is the author of numerous reviews and book chapters on sarcoma.